STIM - NASDAQ

Neuronetics, Inc.

STIM·NASDAQ

$1.39

+2.3%

HealthcareMedical - Diagnostics & Research

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$96.73M

EPS-0.5900

P/E Ratio-2.36

Earnings Date08/04/2026

stim

Net Cash Provided by Financing Activities

Last Annual Value

35.85M

3-Year CAGR

457%

5-Year CAGR

72%

10-Year CAGR

22%

Adjust for Inflation

Neuronetics, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

STIM · NASDAQ

Company	Net Cash Provided by Financing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Neuronetics, Inc. NASDAQ:STIM	35.85M	16.5%	-15.5%	22.0%
Aclaris Therapeutics, Inc. NASDAQ:ACRS	-5.86M	N/A	N/A	N/A
Health Catalyst, Inc. NASDAQ:HCAT	-235.78M	N/A	N/A	N/A
Invivyd, Inc. NASDAQ:IVVD	215.63M	490.9%	-20.1%	N/A
Protara Therapeutics, Inc. NASDAQ:TARA	82.72M	N/A	N/A	82.0%
Sangamo Therapeutics, Inc. NASDAQ:SGMO	70.75M	69.3%	16.6%	70.7%
OraSure Technologies, Inc. NASDAQ:OSUR	-16.94K	N/A	N/A	N/A
Perspective Therapeutics, Inc. AMEX:CATX	10.30M	135.9%	183.8%	N/A
Codexis, Inc. NASDAQ:CDXS	27.93M	50.7%	49.3%	N/A
Atlantic International Corp. NASDAQ:ATLN	3.87M	-24.0%	-20.3%	6.0%
OmniAb, Inc. NASDAQ:OABI	27.91M	N/A	23.5%	N/A

Neuronetics, Inc. Fair Value Envelope

STIM · NASDAQ

Our analysis suggests that STIM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.39, this represents a potential HIDDEN relative to our calculated worth for Neuronetics, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.39

Related Guides

Blog Categories

Continue your STIM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.